Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Preferred Stock Liabilities: 2020-2021

  • Immuneering's Preferred Stock Liabilities was N/A to $82.9 million in Q2 2021 from the same period last year, while for Jun 2021 it was $82.9 million, marking a year-over-year change of. This contributed to the annual value of $58.1 million for FY2020, which is N/A change from last year.
  • Immuneering's Preferred Stock Liabilities amounted to $82.9 million in Q2 2021, which was up 42.66% from $58.1 million recorded in Q4 2020.
  • In the past 5 years, Immuneering's Preferred Stock Liabilities ranged from a high of $82.9 million in Q2 2021 and a low of $58.1 million during Q4 2020.
  • For the 2-year period, Immuneering's Preferred Stock Liabilities averaged around $70.5 million, with its median value being $70.5 million (2020).